Joan M
10-18-2010, 10:34 AM
Some of you may have already seen this Roche update on the T-DM1 trial that's comparing the conjugate drug against the first line treatment of metastatic breast cancer of Herceptin plus docetaxol. The early results thus far at 5.9 months follow-up show comparable tumor shrinkage, and the trial drug shows fewer side effects.
This press release also contains ovarian cancer trial information.
http://www.roche.com/media/media_releases/med-cor-2010-10-11b.htm
Joan
This press release also contains ovarian cancer trial information.
http://www.roche.com/media/media_releases/med-cor-2010-10-11b.htm
Joan